Contrast packaging: Implications for cost and employee safety

Table 1: Follow-up costs associated with percutaneous exposure to at-risk bodily fluids by healthcare workers at two hospitals1

HOSPITAL A
Laboratory
Employee HBsAb$15
Employee HIV antibody panel (ELISA)$25
Source HBsAg$15
Source HIV antibody panel (ELISA)$25

Treatment
HBIG$100
HBV vaccine (3 doses + blood tests)$150
Tetanus$10
AZT + 3TC ± IDV (4-week supply)$650

Service
Emergency department visits$85
Employee health visit (simple)$50
Employee health visit (moderate)$150
Employee health visit (extensive)$250

Other
Employee time$250
Cc99 Ff Dot
TOTAL$1,775
HOSPITAL B
Laboratory
Employee hepatitis profile*$141
Employee HIV antibody panel (ELISA)$56
Employee HCV panel$56
Source hepatitis profile*$141
Source HIV antibody panel (ELISA)$56
Source HCV panel$56

Treatment
HBV vaccine (3 doses)$127
Gamma globulin (5 cc)$8
AZT + 3TC ± IDV (4-week supply)$598
Tetanus$2
HBIG (5 doses)$465

Service
Emergency department visit$40
Employee health visit$60

Other
HBV booster$30
Cc99 Ff Dot
TOTAL$1,836

*(HBsAg, anti-HBs, anti-HBc)
HBsAb = hepatitis B surface antibody; ELISA = enzyme-linked immunosorbent assay; HBsAg = hepatitis B surface antigen; HIV = human immunodeficiency virus; HBIG = hepatitis B immune globulin; HBV = hepatitis B virus; AZT + 3TC ± IDV = Combivir (Glaxo Wellcome, London, U.K.) with or without indinavir; HCV = hepatitis C virus

1Jagger J, Bentley M, Juillet E. Direct cost of follow-up for percutaneous and mucocutaneous exposures to at-risk body fluids: Data from two hospitals. Advanc Exposure Prevent. 1998;3(3):25-34.

Copyright © 2006 AuntMinnie.com

Page 1 of 102
Next Page